IBDEI2H9 ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,39563,2)
 ;;=^5001814
 ;;^UTILITY(U,$J,358.3,39564,0)
 ;;=C92.A0^^152^2000^12
 ;;^UTILITY(U,$J,358.3,39564,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39564,1,3,0)
 ;;=3^Acute Myeloid Leukemia w/ Multilin Dysplasia,Not in Remission
 ;;^UTILITY(U,$J,358.3,39564,1,4,0)
 ;;=4^C92.A0
 ;;^UTILITY(U,$J,358.3,39564,2)
 ;;=^5001813
 ;;^UTILITY(U,$J,358.3,39565,0)
 ;;=C92.51^^152^2000^13
 ;;^UTILITY(U,$J,358.3,39565,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39565,1,3,0)
 ;;=3^Acute Myelomonocytic Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,39565,1,4,0)
 ;;=4^C92.51
 ;;^UTILITY(U,$J,358.3,39565,2)
 ;;=^5001805
 ;;^UTILITY(U,$J,358.3,39566,0)
 ;;=C92.50^^152^2000^14
 ;;^UTILITY(U,$J,358.3,39566,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39566,1,3,0)
 ;;=3^Acute Myelomonocytic Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,39566,1,4,0)
 ;;=4^C92.50
 ;;^UTILITY(U,$J,358.3,39566,2)
 ;;=^5001804
 ;;^UTILITY(U,$J,358.3,39567,0)
 ;;=C94.40^^152^2000^17
 ;;^UTILITY(U,$J,358.3,39567,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39567,1,3,0)
 ;;=3^Acute Panmyelosis w/ Myelofibrosis,Not in Remission
 ;;^UTILITY(U,$J,358.3,39567,1,4,0)
 ;;=4^C94.40
 ;;^UTILITY(U,$J,358.3,39567,2)
 ;;=^5001843
 ;;^UTILITY(U,$J,358.3,39568,0)
 ;;=C94.42^^152^2000^15
 ;;^UTILITY(U,$J,358.3,39568,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39568,1,3,0)
 ;;=3^Acute Panmyelosis w/ Myelofibrosis,In Relapse
 ;;^UTILITY(U,$J,358.3,39568,1,4,0)
 ;;=4^C94.42
 ;;^UTILITY(U,$J,358.3,39568,2)
 ;;=^5001845
 ;;^UTILITY(U,$J,358.3,39569,0)
 ;;=C94.41^^152^2000^16
 ;;^UTILITY(U,$J,358.3,39569,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39569,1,3,0)
 ;;=3^Acute Panmyelosis w/ Myelofibrosis,In Remission
 ;;^UTILITY(U,$J,358.3,39569,1,4,0)
 ;;=4^C94.41
 ;;^UTILITY(U,$J,358.3,39569,2)
 ;;=^5001844
 ;;^UTILITY(U,$J,358.3,39570,0)
 ;;=D62.^^152^2000^18
 ;;^UTILITY(U,$J,358.3,39570,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39570,1,3,0)
 ;;=3^Acute Posthemorrhagic Anemia
 ;;^UTILITY(U,$J,358.3,39570,1,4,0)
 ;;=4^D62.
 ;;^UTILITY(U,$J,358.3,39570,2)
 ;;=^267986
 ;;^UTILITY(U,$J,358.3,39571,0)
 ;;=C92.41^^152^2000^19
 ;;^UTILITY(U,$J,358.3,39571,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39571,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,39571,1,4,0)
 ;;=4^C92.41
 ;;^UTILITY(U,$J,358.3,39571,2)
 ;;=^5001802
 ;;^UTILITY(U,$J,358.3,39572,0)
 ;;=C92.40^^152^2000^20
 ;;^UTILITY(U,$J,358.3,39572,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39572,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,39572,1,4,0)
 ;;=4^C92.40
 ;;^UTILITY(U,$J,358.3,39572,2)
 ;;=^5001801
 ;;^UTILITY(U,$J,358.3,39573,0)
 ;;=D56.0^^152^2000^21
 ;;^UTILITY(U,$J,358.3,39573,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39573,1,3,0)
 ;;=3^Alpha Thalassemia
 ;;^UTILITY(U,$J,358.3,39573,1,4,0)
 ;;=4^D56.0
 ;;^UTILITY(U,$J,358.3,39573,2)
 ;;=^340494
 ;;^UTILITY(U,$J,358.3,39574,0)
 ;;=D63.1^^152^2000^23
 ;;^UTILITY(U,$J,358.3,39574,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39574,1,3,0)
 ;;=3^Anemia in Chronic Kidney Disease
 ;;^UTILITY(U,$J,358.3,39574,1,4,0)
 ;;=4^D63.1
 ;;^UTILITY(U,$J,358.3,39574,2)
 ;;=^332908
 ;;^UTILITY(U,$J,358.3,39575,0)
 ;;=D63.0^^152^2000^24
 ;;^UTILITY(U,$J,358.3,39575,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39575,1,3,0)
 ;;=3^Anemia in Neoplastic Disease
 ;;^UTILITY(U,$J,358.3,39575,1,4,0)
 ;;=4^D63.0
